retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing GLP1 agonists: current and future

Why it matters: Those polydrug blends nicknamed "pink cocaine," "rhino tranq," "benzo-dope" and others are harder to detect, harder to reverse, harder to message against and can even result in the loss of limbs

How does retatrutide cost compare to tirzepatide

See our full comparison

GLP-1 medications are meant for long-term use

Retatrutide's Phase 2a in MASH/MASLD (Sanyal et al., Nat Med 2024) reported approximately 86% relative reduction in liver fat content at 12 mg/week the strongest hepatic-fat data among the incretin class

Your reproductive endocrinologist needs to factor the washout period into your treatment timeline